文献速递消化道肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗原发灶与寡转移灶对比原发灶单独治疗转移性胰腺癌

Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer.
PubMed 文献 · Radiat Oncol · 2024-08-19

该回顾性研究比较立体定向体部放疗(SBRT)照射全部病灶(原发灶及所有寡转移灶)与仅照射原发灶在转移性胰腺癌患者中的疗效与安全性。全部病灶组与仅原发灶组的中位总生存期分别为10.9个月和9.3个月,中位无进展生存期分别为6.5个月和4.1个月,两组3-4级治疗相关毒性发生率分别为23.7%和20.2%。作者认为照射全部寡转移灶可能改善生存,但需前瞻性验证。

要点

  • 全部病灶组中位总生存期10.9个月(95%CI 10.2-11.6),仅原发灶组9.3个月(95%CI 8.8-9.8),P<0.001。
  • 全部病灶组3-4级治疗相关毒性14例(23.7%),仅原发灶组32例(20.2%)。
  • 作者认为SBRT照射全部寡转移灶及原发灶可能改善生存,需前瞻性验证。

核心结论

  • 对胰腺癌患者的全部寡转移灶及原发灶行SBRT可能改善生存,该结论需前瞻性验证。

研究设计与样本

  • 回顾性研究,比较接受SBRT照射全部病灶(包括所有寡转移灶和原发灶)的同步寡转移胰腺癌(病灶数不超过5个)患者与基线特征(包括转移负荷、SBRT剂量和化疗方案)相似的仅接受原发灶SBRT的患者。
  • 全部病灶组59例,仅原发灶组158例。
  • 主要终点为总生存期,次要终点为无进展生存期、无多病灶进展生存期及不良事件。

主要发现

  • 全部病灶组中位总生存期10.9个月(95%CI 10.2-11.6),仅原发灶组9.3个月(95%CI 8.8-9.8),P<0.001。
  • 全部病灶组中位无进展生存期6.5个月(95%CI 5.6-7.4),仅原发灶组4.1个月(95%CI 3.8-4.4),P<0.001。
  • 全部病灶组中位无多病灶进展生存期9.8个月(95%CI 8.9-10.7),仅原发灶组7.8个月(95%CI 7.2-8.4),P<0.001。
  • 全部病灶组3-4级治疗相关毒性14例(23.7%),仅原发灶组32例(20.2%)。

临床怎么用

  • 作者认为对胰腺癌患者的全部寡转移灶及原发灶行SBRT可能改善生存,需前瞻性验证。

局限性

  • 原文未报告局限性;作者在结论中指出该发现需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Local therapies may benefit patients with oligometastatic cancer. However, there were limited data about pancreatic cancer. Here, we compared the efficacy and safety of stereotactic body radiation therapy (SBRT) to the primary tumor and all oligometastases with SBRT to the primary tumor alone in patients with metastatic pancreatic cancer. METHODS: A retrospective review of patients with synchronous oligometastatic pancreatic cancer (up to 5 lesions) receiving SBRT to all lesions (including all oligometastases and the primary tumor) were performed. Another comparable group of patients with similar baseline characteristics, including metastatic burden, SBRT doses, and chemotherapy regimens, receiving SBRT to the primary tumor alone were identified. The primary endpoint was overall survival (OS). The secondary endpoints were progression frees survival (PFS), polyprogression free survival (PPFS) and adverse events. RESULTS: There were 59 and 158 patients receiving SBRT to all lesions and to the primary tumor alone. The median OS of patients with SBRT to all lesions and the primary tumor alone was 10.9 months (95% CI 10.2-11.6 months) and 9.3 months (95% CI 8.8-9.8 months) (P < 0.001). The median PFS of two groups was 6.5 months (95% CI 5.6-7.4 months) and 4.1 months (95% CI 3.8-4.4 months) (P < 0.001). The median PPFS of two groups was 9.8 months (95% CI 8.9-10.7 months) and 7.8 months (95% CI 7.2-8.4 months) (P < 0.001). Additionally, 14 (23.7%) and 32 (20.2%) patients in two groups had grade 3 or 4 treatment-related toxicity. CONCLUSIONS: SBRT to all oligometastases and the primary tumor in patients with pancreatic cancer may improve survival, which needs prospective verification.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Jiang L, Ye Y, Feng Z, et al. Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer. Radiat Oncol. 2024. PMID: 39160547. doi:10.1186/s13014-024-02493-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。